查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492228

Canavan 疾病治疗药物市场：治疗方法、最终用户、分销管道 - 全球预测 2024-2030

Canavan Disease Therapeutics Market by Treatment (Gene therapy, Medication, Supportive Treatments), End-user (Homecare, Hospitals, Specialty clinics), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Canavan疾病治疗药物市场规模预计2023年为5.2729亿美元，预计2024年将达到5.5666亿美元，预计2030年将达到7.871亿美元，预计复合年增长率为5.88%。

卡纳万病医学是开髮用于管理和解决卡纳万病根本原因的治疗方法和药物。由于神经纤维髓鞘周围的保护鞘劣化，这种疾病会影响大脑发送和接收讯息的能力。基因治疗和基因工程的创新对于开发卡纳万病的根治性治疗方法至关重要。此外，对频繁诊断的认识不断提高，随后需要开发治疗卡纳万病的药物。然而，罕见疾病的研究、开发和治疗需要大量投入，往往导致患者负担增加。此外，CRISPR 和其他基因编辑技术有足够的潜力开发明确的治疗方法。生物技术公司、大学和研究机构之间的合作可以在未来几年加速卡纳万疾病治疗的发展。

主要市场统计
基准年[2023] 5.2729亿美元
预测年份 [2024] 55666万美元
预测年份 [2030] 7.871 亿美元
复合年增长率（%） 5.88%

区域洞察

美洲拥有发达的医疗保健系统和对生物技术研究的大力投资，使其成为开发卡纳万病等罕见疾病治疗方法的温床。美国专利界组织良好，专注于创新基因治疗解决方案，旨在解决卡纳万病的遗传根源。加拿大消费者更信任他们的医疗保健提供者，更有可能参与临床试验，从而加快药物开发速度。政府在医疗保健方面的发展资金和监管审批措施正在改善获得新治疗方法的机会。在欧盟（EU），基因治疗研究以及透过临床试验资料库进行病患登记的合作在新治疗方法的开发中发挥重要作用。沙乌地阿拉伯和阿联酋等中东主要国家对临床研究基础设施和医疗设施进行了大量投资，以促进该地区对罕见疾病的研究。非洲地区在卡纳万病治疗方面取得了进展，投资增加导致医疗设施和基础设施的普及。在亚太地区，有关将罕见疾病纳入医疗保健的政府倡议和国家政策为该地区的市场扩张铺平了道路。日本、印度和中国等国家的市场成长是由支持新治疗方法开拓和罕见疾病相关资讯传播的法规环境所推动的。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在 Canavan 疾病治疗药物市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对 Canavan 疾病治疗市场供应商的现状进行深入而详细的评估。对供应商贡献的彻底比较和分析可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对 Canavan 疾病治疗市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 卡纳万病患病率增加
      • 改进诊断技术并提高全球对卡纳万病的认识
    • 抑制因素
      • 治疗成本高且商业化受到限制
    • 机会
      • 基因治疗技术的重大进展
      • 研究机构与製药公司的策略合作
    • 任务
      • 卡纳万病药物开发中的监管和标准化挑战
  • 市场区隔分析
    • 治疗：基因疗法在卡纳万病治疗的新应用
    • 最终用户：医院更多采用卡纳万病药物
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 Canavan 疾病治疗药物市场（依治疗）

  • 基因治疗
  • 药物治疗
  • 支持性护理

第七章 Canavan 疾病治疗药物市场：依最终使用者分类

  • 居家护理
  • 医院
  • 专科诊所

第八章 Canavan 疾病治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲卡纳万病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区Canavan疾病治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲Canavan疾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Myrtelle Inc. 的 rAAV-Olig001-ASPA 已获得美国食品药物管理局(FDA)核准。
    • NADER计划：Burjeel Holdings 和 BridgeBio Pharma, Inc. 发起的罕见疾病早期诊断和治疗计画。
    • BridgeBio Pharma, Inc. 与 National Resilience, Inc. 结成策略联盟，加强罕见疾病基因治疗药物的生产
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-99555D550525

[186 Pages Report] The Canavan Disease Therapeutics Market size was estimated at USD 527.29 million in 2023 and expected to reach USD 556.66 million in 2024, at a CAGR 5.88% to reach USD 787.10 million by 2030.

Canavan disease therapeutics is the development of treatments and medications to manage and address the underlying causes of Canavan disease. This disease affects the brain's ability to send and receive messages due to the deterioration of the protective sheath around nerve fibers myelin. Innovations in gene therapy and genetic engineering are crucial for developing curative treatments for Canavan disease. Additionally, growing awareness of frequent diagnosis subsequently generated the need to develop Canavan disease therapeutics. However, research, development, and treatment of rare diseases require high investment, often resulting in increased patient costs. Furthermore, CRISPR and other gene-editing technologies hold sufficient capabilities for developing definitive treatments. Collaborations between biotech companies, universities, and research institutes can accelerate the development of Canavan disease therapeutics in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 527.29 million
Estimated Year [2024] USD 556.66 million
Forecast Year [2030] USD 787.10 million
CAGR (%) 5.88%

Regional Insights

In the Americas, developed healthcare systems and significant investments in biotechnology research make it an arena for the development of treatments for rare diseases such as Canavan disease. The patent community in the U.S. is well-organized and focuses on innovative gene therapy solutions aiming to address the genetic root of the Canavan disease. The tendency of Canadian consumers to show a high trust in healthcare providers and participation in clinical trials makes the advancement of drug development faster. The government initiatives related to funding and regulatory clearance for development in healthcare improve access to new therapies. In the European Union, collaborations on gene therapy research and patient registries with clinical trial databases played a crucial role in the development of new treatments. Major Middle Eastern countries, including Saudi Arabia and the United Arab Emirates, showed robust investments in clinical research infrastructure and medical facilities, fostering local research for rare diseases. The African region showed development in Canavan disease therapeutics due to the growing penetration of healthcare facilities and infrastructure due to rising investments. In the APAC region, government initiatives about the incorporation of rare diseases in healthcare initiatives and state policies paved the way for the expansion of the market in the region. A supportive regulatory environment for the development of new therapies and proper information dissemination about rare diseases cater to market growth in countries such as Japan, India, and China.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Canavan Disease Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of canavan disease
      • Enhanced diagnostic techniques and increased global awareness about canavan disease
    • Market Restraints
      • High cost of treatment coupled with limited commercialization
    • Market Opportunities
      • Significant advancements in gene therapy techniques
      • Strategic collaborations between research institutes and pharmaceutical companies
    • Market Challenges
      • Regulatory and standardization challenges in canavan disease therapeutics development
  • Market Segmentation Analysis
    • Treatment: Emerging application of gene therapy to treat Canavan disease
    • End-user: Increasing adoption of Canavan disease therapeutics in hospitals
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Canavan Disease Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Canavan Disease Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Myrtelle Inc. received approval from the U.S. Food and Drug Administration (FDA) for rAAV-Olig001-ASPA

Myrtelle Inc., a company focused on creating treatments for brain disorders, has received special attention from the U.S.A. FDA for its new gene therapy, named rAAV-Olig001-ASPA, aimed at treating Canavan disease (CD). The therapy works by targeting specific brain cells called oligodendrocytes, which are essential for producing myelin - a protective layer that ensures neurons function correctly. [Published On: 2024-04-02]

Project NADER: An Initiative for Early Diagnosis and Treatment of Rare Diseases by Burjeel Holdings and BridgeBio Pharma, Inc.

Burjeel Holdings and BridgeBio Pharma, Inc. have initiated Project NADER, a venture to enhance the diagnosis of rare diseases in the UAE. This collaboration encapsulated a spectrum of rare disorders, such as Canavan disease, achondroplasia, and several others, aimed to harness Abu Dhabi's infrastructure for advancements in life sciences [Published On: 2023-12-07]

Strategic Collaboration between BridgeBio Pharma, Inc. and National Resilience, Inc. to Boost Gene Therapy Manufacturing for Rare Diseases

BridgeBio Pharma, Inc., a genetic disease and cancer therapeutics company, has announced a partnership with National Resilience, Inc., a firm in biomanufacturing innovations, to elevate the production and development of two investigational gene therapies such as BBP-812 for Canavan disease and BBP-631 for congenital adrenal hyperplasia. This strategic alliance will incorporate National Resilience, Inc.'s advanced manufacturing capabilities to support and potentially expedite the commercial availability of these therapies. [Published On: 2023-03-10]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Canavan Disease Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Canavan Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Amgen, Inc., Anjarium Biosciences AG, Astellas Pharma Inc., Biogen Inc., BridgeBio Pharma, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Myrtelle, Inc., Novartis AG, Orchard Therapeutics PLC, Orphan Star Therapeutics LLC, Pfizer, Inc., Sanofi SA, Sio Gene Therapies Inc., Ultragenyx Pharmaceutical Inc., and Voyager Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Canavan Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Gene therapy
    • Medication
    • Supportive Treatments
  • End-user
    • Homecare
    • Hospitals
    • Specialty clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of canavan disease
      • 5.1.1.2. Enhanced diagnostic techniques and increased global awareness about canavan disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with limited commercialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant advancements in gene therapy techniques
      • 5.1.3.2. Strategic collaborations between research institutes and pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and standardization challenges in canavan disease therapeutics development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Emerging application of gene therapy to treat Canavan disease
    • 5.2.2. End-user: Increasing adoption of Canavan disease therapeutics in hospitals
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Canavan Disease Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Gene therapy
  • 6.3. Medication
  • 6.4. Supportive Treatments

7. Canavan Disease Therapeutics Market, by End-user

  • 7.1. Introduction
  • 7.2. Homecare
  • 7.3. Hospitals
  • 7.4. Specialty clinics

8. Canavan Disease Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Canavan Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Canavan Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Canavan Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Myrtelle Inc. received approval from the U.S. Food and Drug Administration (FDA) for rAAV-Olig001-ASPA
    • 12.3.2. Project NADER: An Initiative for Early Diagnosis and Treatment of Rare Diseases by Burjeel Holdings and BridgeBio Pharma, Inc.
    • 12.3.3. Strategic Collaboration between BridgeBio Pharma, Inc. and National Resilience, Inc. to Boost Gene Therapy Manufacturing for Rare Diseases
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CANAVAN DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANAVAN DISEASE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANAVAN DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUPPORTIVE TREATMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUPPORTIVE TREATMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023